Edition:
United States

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

1.20EUR
14 Dec 2017
Change (% chg)

€-0.01 (-0.50%)
Prev Close
€1.21
Open
€1.21
Day's High
€1.22
Day's Low
€1.19
Volume
9,342,057
Avg. Vol
30,747,314
52-wk High
€1.38
52-wk Low
€0.22

Chart for

About

Pharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company’s products... (more)

Overall

Beta: -0.68
Market Cap(Mil.): €655.39
Shares Outstanding(Mil.): 546.16
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Pharming Group Announces Significant Conversion Of Its Ordinary Convertible Bonds

* PHARMING ANNOUNCES SIGNIFICANT CONVERSION OF ITS ORDINARY CONVERTIBLE BONDS

Dec 05 2017

BRIEF-Pharming Submits License Application to FDA for Ruconest

* PHARMING SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

Nov 27 2017

BRIEF-Pharming Group Q3 net result swings to profit of 7.5 million euros from Q2

* ‍Q3 NET RESULT IMPROVED TO EUR 7.5 MILLION LOSS COMPARED WITH A LOSS OF EUR 24.5 MILLION IN Q2​

Oct 26 2017

BRIEF-Pharming Group announces positive data from paediatric clinical trial of Ruconest

* PHARMING ANNOUNCES POSITIVE DATA FROM PAEDIATRIC CLINICAL TRIAL WITH RUCONEST®

Oct 02 2017

BRIEF-Pharming Group partners with Inceptua Medicines Access

* PHARMING GROUP N.V. AND HAEI INTERNATIONAL PATIENT ORGANIZATION ANNOUNCE PARTNERSHIP WITH INCEPTUA MEDICINES ACCESS FOR "HAEI GLOBAL ACCESS PROGRAM"

Sep 26 2017

BRIEF-Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest

* PHARMING ANNOUNCES CONCLUSION OF FDA END OF PHASE 2 INTERACTIONS ON RUCONEST FOR PROPHYLAXIS OF HAE

Sep 11 2017

BRIEF-Pharming Group announces cashless warrant exercises and conversions of its ordinary bonds into shares

* ANNOUNCES CASHLESS WARRANT EXERCISES AND CONVERSIONS OF ITS ORDINARY BONDS INTO SHARES

Aug 10 2017

BRIEF-Pharming Group H1 net loss widens to 30.2 million euros

* SAID ON THURSDAY THAT REVENUES FROM PRODUCT SALES FOR THE HALF YEAR INCREASED BY 617 PCT TO EUR 30.1 MILLION (HY 2016: EUR 4.2 MILLION)

Jul 27 2017

BRIEF-Pharming announces publication of Ruconest prophylactic data in The Lancet

* PHARMING ANNOUNCES PUBLICATION OF RUCONEST PROPHYLACTIC DATA IN THE LANCET Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 26 2017

BRIEF-Pharming group announces completion of replacement of its 100 million dollars bridge finance

* ANNOUNCES THAT IT HAS COMPLETED REPLACEMENT OF ITS RECENTLY ANNOUNCED US$100 MILLION BRIDGE FINANCE WITH ORBIMED ADVISORS

Jul 21 2017

Earnings vs. Estimates